Breaking News

Tweet TWEET

Annual Report for 2013 on Form 20-F filed with the SEC on April 4, 2014

   Annual Report for 2013 on Form 20-F filed with the SEC on April 4, 2014  PR Newswire  BARCELONA, Spain, April 4, 2014  BARCELONA, Spain, April 4, 2014 /PRNewswire/ --Grifols, S.A. ("Grifols") (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), announced that it has filed its 2013 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 4, 2014. Grifols' Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended December 31, 2013.  Form 20-F can be accessed electronically through the Grifols website at http://inversores.grifols.com/portal/es/grifols/sec_filings. The Form 20-F is also available on the SEC's website at http://www.sec.gov .  Grifols will deliver, within a reasonable time after request, a hard copy of the Form 20-F, including its complete audited financial statements, free of charge, to any shareholder upon request. To request a hard copy, shareholders may contact Grifols by email at investors@grifols.com to the attention of Grifols's Investor Relations, Re: 2013 Annual Report on Form 20-F.  About Grifols Grifols is a global healthcare company with a 70-year legacy of improving people's health and well being through the development of life-saving plasma medicines, diagnostics systems, and hospital pharmacy products.  The company is present in more than 100 countries worldwide and is headquartered in Barcelona, Spain. Grifols is a leader in plasma collection with a network of 150 plasma donor centers in the U.S., and a leading producer of plasma-derived biological medicines. The company also provides a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood banks and transfusion centers, and is a recognized leader in transfusion medicine.  In 2013, sales exceeded 2,740 million euros with a headcount of 13,200 employees. Grifols demonstrates its commitment to advancing healthcare by allocating a significant portion of its annual income to R&D.  The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit www.grifols.com.  SOURCE Grifols, S.A.  Website: http://www.grifols.com Contact: Punkaj Amin, 1-919-316-6664  
Press spacebar to pause and continue. Press esc to stop.